J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Estrogen receptor α/β isoforms, but not βcx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells
TL;DR: It is demonstrated here that ERα and ERβ regulate unique gene expression patterns in Hs578T cells, and such regulation likely is responsible for the observed isoform‐specific changes in cell proliferation.
Journal ArticleDOI
Pericardial Effusion in Women With Breast Cancer
TL;DR: Small, clinically unsuspected pericardial effusions appear to be relatively common in women with metastatic breast cancer and echocardiography performed on a routine basis, and nonsurgical therapy in patients with histologically proven or clinically suspected malignant pericARDial effusion was associated with a high incidence of progessive perICardial disease.
Journal ArticleDOI
Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus
Ianko D. Iankov,Cory Allen,Mark J. Federspiel,Rae Myers,Kah Whye Peng,James N. Ingle,Stephen J. Russell,Evanthia Galanis +7 more
TL;DR: The data suggest that potent immunomodulators of bacterial origin, such as H. pylori NAP, can enhance the antitumor effect of oncolytic viruses and support the feasibility and potential of a combined viroimmunotherapy approach.
Journal ArticleDOI
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
Xianglin Wu,Malayannan Subramaniam,Vivian Negron,Muzaffer Cicek,Carol Reynolds,Wilma L. Lingle,Matthew P. Goetz,James N. Ingle,Thomas C. Spelsberg,John R. Hawse +9 more
TL;DR: Evidence is provided that much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer may be explained by variability in antibody sensitivity and specificity and the use of the MC10 antibody, in combination with highly specific antibodies targeting only full‐length ERβ, is likely to provide additional discriminatory features in breast cancers.
Journal ArticleDOI
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy
Zahraa Al-Hilli,Grace M. Choong,Michael G. Keeney,Daniel W. Visscher,James N. Ingle,Matthew P. Goetz,James W. Jakub +6 more
TL;DR: MetaBC is poorly responsive to NAC, with a pCR rate that is lower than expected in a predominantly TNBC cohort and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.